ARS Pharmaceuticals posts Phase 2 results for intranasal epinephrine ARS-1 in asthma
Results from a completed crossover trial compared ARS-1 to albuterol and placebo in persistent asthma patients.
- The trial, "A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma" (NCT05363670), sponsored by ARS Pharmaceuticals, Inc.,1 is listed as completed, with primary completion and study completion both dated 2024-02-02 (actual)1 and results first posted 2026-07-14. The study enrolled 18 participants1 across four sites in the United States, including University of South Florida, Institute for Asthma and Allergy, Massachusetts General Hospital, and Bernstein Clinical Research Center, LLC1.
- Posted results for the primary outcome, change in FEV1 from baseline to 1 hour, showed ARS-1 1mg at 0.150 L, ARS-1 2mg at 0.233 L, placebo at -0.002 L, and albuterol at 0.378 L1. No serious adverse events were reported: 0 of 18 participants had serious adverse events in each of the ARS-1 1mg, ARS-1 2mg, placebo, and albuterol arms1.
Fact check notes
- Checker's noteThe claim that this was posted 'this week' is not supported by the source, which only lists a results-first-posted date of 2026-07-14 without confirming recency relative to publication.
- Sentence removed
ARS Pharmaceuticals had one item posted this week, a completed Phase 2 trial with results now available.
unsupported: Source gives no indication of 'this week' timing; results first posted date is 2026-07-14 but no confirmation this is 'this week'.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.